Posted on 29/03/202129/03/2021Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial
Posted on 29/03/202129/03/2021The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy
Posted on 26/03/202126/03/2021ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
Posted on 23/03/202123/03/2021Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
Posted on 23/03/202123/03/2021Genentech Provides Update on Tominersen Program in Manifest Huntington’s Disease: Dosing to stop in Phase III clinical study of tominersen
